Business Description
XTL Biopharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : US98386D3070
Share Class Description:
FRA:H2K2: ADRCompare
Compare
Traded in other countries / regions
XTLB.IsraelXTLB.USAH2K2.Germany IPO Date
2007-03-15Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.92 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.6 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | 5.9 | |||||
| 3-Year Book Growth Rate | -16.8 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.86 | |||||
| 9-Day RSI | 41.02 | |||||
| 14-Day RSI | 42.09 | |||||
| 6-1 Month Momentum % | -5.41 | |||||
| 12-1 Month Momentum % | 127.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.43 | |||||
| Quick Ratio | 11.43 | |||||
| Cash Ratio | 10.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -14.29 | |||||
| ROA % | -13.29 | |||||
| ROIC % | -181.35 | |||||
| ROCE % | 23.8 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PB Ratio | 3.5 | |||||
| Price-to-Tangible-Book | 3.94 | |||||
| EV-to-EBIT | 11.17 | |||||
| EV-to-EBITDA | 11.17 | |||||
| EV-to-FCF | -9.97 | |||||
| Price-to-Net-Current-Asset-Value | 3.15 | |||||
| Price-to-Net-Cash | 6.3 | |||||
| Earnings Yield (Greenblatt) % | 8.95 | |||||
| FCF Yield % | -7.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
XTL Biopharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.03 | ||
| Beta | 3.32 | ||
| Volatility % | 272.5 | ||
| 14-Day RSI | 42.09 | ||
| 14-Day ATR (€) | 0.085339 | ||
| 20-Day SMA (€) | 1.559 | ||
| 12-1 Month Momentum % | 127.27 | ||
| 52-Week Range (€) | 0.65 - 3.06 | ||
| Shares Outstanding (Mil) | 5.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
XTL Biopharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XTL Biopharmaceuticals Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
XTL Biopharmaceuticals Ltd Frequently Asked Questions
What is XTL Biopharmaceuticals Ltd(FRA:H2K2)'s stock price today?
The current price of FRA:H2K2 is €1.33. The 52 week high of FRA:H2K2 is €3.06 and 52 week low is €0.65.
When is next earnings date of XTL Biopharmaceuticals Ltd(FRA:H2K2)?
The next earnings date of XTL Biopharmaceuticals Ltd(FRA:H2K2) is 2024-12-30 Est..
Does XTL Biopharmaceuticals Ltd(FRA:H2K2) pay dividends? If so, how much?
XTL Biopharmaceuticals Ltd(FRA:H2K2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers